Overview
For decades, diagnosing Alzheimer's meant either a $5,000 brain scan with radiation exposure or a painful spinal tap. In October 2025, the FDA cleared Roche's blood test for use in primary care—a simple blood draw that rules out Alzheimer's 97.9% of the time. It's the second blood test approved in five months, transforming a diagnosis that once required specialists and imaging centers into something your family doctor can order.
The stakes are massive: 7.2 million Americans have Alzheimer's, costing $384 billion annually in care. New drugs like Leqembi and Kisunla can slow the disease—but only if patients get diagnosed early, before severe cognitive decline. Blood tests could catch cases years earlier than current methods, finally making the disease detectable when treatment actually works.
Key Indicators
People Involved
Organizations Involved
Swiss pharmaceutical and diagnostics giant pioneering blood-based Alzheimer's biomarker testing.
Japanese diagnostics company that won FDA clearance for the first Alzheimer's blood test in May 2025.
St. Louis-based company pioneering mass spectrometry-based Alzheimer's blood tests.
Pharmaceutical giant developing both Alzheimer's treatments and the diagnostics to identify eligible patients.
Federal agency whose reimbursement decisions determine whether blood tests become economically viable.
Major lab operator making Alzheimer's blood tests available at 2,200+ patient service centers.
Lab giant offering both physician-ordered and controversial direct-to-consumer Alzheimer's tests.
Timeline
-
Bipartisan ASAP Act Introduced
LegislativeCongress introduces bill creating Medicare pathway for FDA-cleared blood biomarker screening tests.
-
FDA Clears Roche Test for Primary Care
RegulatoryElecsys pTau181 becomes first blood test cleared specifically for primary care use, ruling out disease 97.9% of the time.
-
C2N Submits FDA Application
RegulatoryC2N files first multi-analyte algorithmic blood test using high-resolution mass spectrometry for FDA review.
-
Labcorp Launches Lumipulse Nationwide
CommercialFirst FDA-cleared test becomes available at 2,200+ Labcorp patient service centers across United States.
-
Roche Receives European CE Mark
RegulatoryElecsys pTau181 test receives CE Mark certification, clearing path for European market entry.
-
FDA Clears First Alzheimer's Blood Test
RegulatoryFujirebio's Lumipulse becomes first FDA-cleared blood test, measuring pTau217/Aβ1-42 ratio with 91.7% positive predictive value.
-
Fujirebio Discovers Manufacturing Issues
QualityAt CTAD conference, Fujirebio identifies problems with commercial lots, placing Lumipulse product on quality hold.
-
CMS Finalizes $130 Reimbursement Rate
PolicyAfter proposing just $17, CMS sets $130 Medicare reimbursement, making tests economically viable for labs.
-
FDA Approves Kisunla, Second Anti-Amyloid Drug
TreatmentDonanemab approval intensifies pressure for accessible diagnostics, as drug only works in early-stage disease.
-
Roche-Lilly Test Gets Breakthrough Designation
RegulatoryFDA grants Roche's Elecsys pTau217 test Breakthrough Device designation, expediting review for partnership with Eli Lilly.
-
Quest Launches Controversial Direct-to-Consumer Test
CommercialQuest introduces direct-to-consumer Alzheimer's blood test, sparking debate about testing without physician guidance.
-
FDA Approves Leqembi, First Disease-Modifying Drug
TreatmentLecanemab becomes first therapy proven to slow Alzheimer's cognitive decline, creating urgent need for early diagnostic tools.
-
C2N Receives First Breakthrough Device Designation
RegulatoryFDA grants C2N Diagnostics Breakthrough Device designation for its mass spectrometry-based blood test, beginning the regulatory sprint.
Scenarios
Blood Tests Become Standard of Care in Primary Medicine
Discussed by: Alzheimer's Association, Mayo Clinic researchers, diagnostic industry analysts
With Medicare covering tests at $130 and major labs offering nationwide availability, primary care physicians routinely order blood tests during annual wellness visits for patients over 65. Early detection increases dramatically, catching disease 3-5 years before traditional diagnosis. New drug treatments work better when started early. Deaths from Alzheimer's begin declining for the first time in decades. Additional biomarkers get approved, creating diagnostic panels. The $5,000 brain scan becomes reserved only for ambiguous cases.
Quality and Accuracy Issues Undermine Confidence
Discussed by: ALZFORUM, medical journal editorials, consumer advocacy groups
Manufacturing problems like Fujirebio's quality hold prove systemic across blood test makers. False positives create anxiety and unnecessary follow-up testing. Variations between labs produce inconsistent results. Primary care doctors, lacking dementia expertise, misinterpret findings. High-profile misdiagnosis cases emerge. Medicare restricts coverage pending additional validation. Adoption stalls as specialists question whether tests are ready for widespread use outside research settings.
Direct-to-Consumer Testing Creates Diagnostic Chaos
Discussed by: Bioethics experts, ALZFORUM commentators, neurologist associations
Quest's direct-to-consumer model expands as competitors follow. Millions of worried middle-aged people order tests without medical supervision. Many receive positive results but lack access to new treatments due to insurance barriers or geographic constraints. Anxiety and depression spike among those testing positive who can't afford $26,500 annual drug costs. Memory clinics overwhelmed with patients seeking confirmatory testing. Regulatory crackdown on direct marketing of tests without physician involvement.
New Biomarkers Outpace Current Generation
Discussed by: Nature Medicine researchers, pharmaceutical companies developing diagnostics
Research identifies superior biomarkers beyond pTau217 and pTau181, such as neurofilament light chain or novel inflammatory markers. Next-generation tests combine multiple biomarkers into algorithmic scores with 99%+ accuracy. Companies like C2N gain market advantage with mass spectrometry platforms. First-generation tests from Roche and Fujirebio become obsolete within 3-4 years. Labs face costly equipment upgrades. Early adopters regret infrastructure investments in soon-outdated technology.
Historical Context
HIV Antibody Test Approval (1985)
1985-1990What Happened
FDA approved the first blood test detecting HIV antibodies in March 1985, three years after HIV was identified as the cause of AIDS. The test transformed a death sentence into a manageable chronic disease by enabling early treatment. However, initial rollout faced controversy over false positives, stigma, and questions about testing without available treatments.
Outcome
Short term: Testing initially limited to blood banks and high-risk populations, with significant debate over mandatory testing.
Long term: Blood testing became routine medical practice, enabling the antiviral revolution that turned HIV into a manageable condition.
Why It's Relevant
Like HIV testing, Alzheimer's blood tests arrive alongside new treatments (Leqembi, Kisunla) that work best when disease is caught early—but raise similar questions about testing people when treatments aren't universally accessible.
PSA Test for Prostate Cancer (1994)
1994-2012What Happened
FDA approved PSA blood testing for prostate cancer screening in 1994, promising early detection through simple blood draws instead of biopsies. Adoption soared. By 2008, most men over 50 were getting regular PSA tests. However, studies revealed widespread overdiagnosis and overtreatment—many men received aggressive treatment for slow-growing cancers that would never have harmed them.
Outcome
Short term: PSA testing became standard of care, with millions of men screened annually and prostate cancer detection increasing sharply.
Long term: In 2012, the US Preventive Services Task Force recommended against routine PSA screening after data showed harms outweighed benefits for most men.
Why It's Relevant
Cautionary tale for Alzheimer's blood tests: early detection isn't always beneficial if treatments are limited, expensive, or carry significant side effects—and if tests generate false positives causing unnecessary anxiety.
Theranos Blood Testing Scandal (2015-2018)
2015-2018What Happened
Theranos claimed revolutionary blood testing technology using fingerprick samples, attracting $700 million in investment and partnerships with Walgreens. Investigative journalism revealed the technology didn't work—tests were inaccurate and the company used traditional machines for most analyses. Founder Elizabeth Holmes was convicted of fraud. The scandal traumatized the blood testing industry.
Outcome
Short term: Theranos collapsed, investors lost hundreds of millions, and regulatory scrutiny of diagnostic startups intensified dramatically.
Long term: FDA tightened oversight of laboratory-developed tests; investors became cautious about diagnostic companies; public trust in blood testing innovation damaged.
Why It's Relevant
The Theranos shadow looms over Alzheimer's blood tests—explaining why FDA demanded rigorous validation, why some experts questioned Quest's direct-to-consumer model, and why Fujirebio's manufacturing issues triggered immediate concern.